LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

The PREVAIL Study: intensive models of HCV care for people who inject drugs

Photo by aaronburden from unsplash

Methods: PREVAIL is a randomized controlled trial that enrolled HCV-infected (genotype 1) PWID maintained on OAT, including those actively using drugs. Participants were randomized to one of three models of… Click to show full abstract

Methods: PREVAIL is a randomized controlled trial that enrolled HCV-infected (genotype 1) PWID maintained on OAT, including those actively using drugs. Participants were randomized to one of three models of HCV care delivered on-site in an OAT program: 1) directly observed treatment (DOT), 2) group medical visit (Group), or 3) individual treatment as usual (TAU). Participants received DAAs according to AASLD guidelines: telaprevir/pegylated interferon/ribavirin (TVR/PEG/RBV), sofosbuvir/ribavirin (SOF/RBV), sofosbuvir/pegylated interferon/ribavirin (SOF/PEG/RBV), sofosbuvir/simeprevir (SOF/SMV), or sofosbuvir/ledipasvir (SOF/LDV). The primary outcome was SVR12 and secondary outcomes were end of treatment response (ETR) and SVR12. Drug use (opiates, cocaine, and benzodiazepines) was assessed through urine screens. Differences by arm were tested by a Fisher exact test, and the 95% confidence interval (CI) for virological outcomes were determined by the ClopperPearson method.

Keywords: rbv sofosbuvir; prevail study; sof; hcv care; models hcv

Journal Title: Journal of Hepatology
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.